Dose‐Related Safety and Immunogenicity of Baculovirus‐Expressed Trivalent Influenza Vaccine: A Double‐Blind, Controlled Trial in Adult Patients with Non‐Hodgkin B Cell Lymphoma

Abstract
In 27 patients randomized to receive commercial trivalent influenza vaccine (TIV) containing 15 μg of the hemagglutinin (HA) of influenza A (H3N2 and

This publication has 0 references indexed in Scilit: